cyrilzakka/clinical-trials huggingface dataset:
Comparison of Effects of Mobilization With Movement and Kinesiotaping in Patellofemoral Pain Syndrome

Patellofemoral Pain Syndrome (PFPS), also known as the anterior knee pain, is one of the most common musculoskeletal disorders. Most of the patients suffer from knee pain for long time. The aim of this study was to investigate the short-term effects of Mobilization with movement and Kinesiotaping on pain, function and balance in patient with PFPS.

Patellofemoral Pain Syndrome is one of the most common musculoskeletal problem in the world. It's incidence is also becoming higher and most people who have knee pain suffer from it for long time. In the treatment of PFPS, conservative treatment methods are preferred prior to surgical ones. When the literature was reviewed, no study in which Mobilization with movement (MWM) method was used and in which the effects of it was shown and compared with (Kinesiotaping) KT has been found so far with respect to the treatment of PFPS. Thirty-five female patients diagnosed with unilateral PFPS were randomly assigned into 2 groups. The patients in the first group (n=18) received two techniques of Mobilization with movement intervention while Kinesiotaping was applied to the other group (n=17). Both groups were treated with exercise. All patients received 4 sessions of treatment twice a week for a period of 2 weeks and followed up in accordance with a 6-week-home exercise program. Primary outcomes: pain severity, knee range of motion, hamstring flexibility, and physical performance (10-step stair climbing test, timed up and go test), Kujala Patellofemoral Pain Scoring and Y-Balance test were assessed.

Eligibility Criteria:
Inclusion Criteria:

* having knee pain at least 3 months and more than 3 points according to visual analog scale

Exclusion Criteria:

* no complying to the rehabilitation
* if patient wants to finished and want to complete study, they were excluded
* having meniscus, bursa, ligament, patellar tendon lesions, patellofemoral dislocation and/or recurrent subluxation, undergone lower extremity surgery
Stem Cell Educator Therapy in Type 2 Diabetes

Type 2 diabetes is the most common form of diabetes. The prevalence of diabetes has been markedly increased in recent years. More and more children and young adults develop this devastating disease. Despite of multiple factors (e.g., food, environmental, and genetic factors) contributing to the developing of diabetes, increasing evidence demonstrated that chronic inflammation and/or atuoimmunity are common issues and play key roles in the pathogenesis of type 2 diabetes, leading to the insulin resistance and the shortage of insulin-producing islet beta cells. Thus, anti-inflammation is becoming a novel approach for the treatment of type 2 diabetes. Evidence that multipotent stem cells derived from human cord blood (CB-SCs) can control inflammation and autoimmune responses by altering regulatory T cells (Tregs) and human islet beta cell-specific T cell clone in type 1 diabetes offers promise for a new approach to treat type 2 diabetes. Here, the investigators develop a novel Stem Cell Educator therapy by using CB-SC and explore the therapeutic effectiveness of Stem Cell Educator therapy in T2D patients.


Eligibility Criteria:
Inclusion Criteria:

* Patients were screened for enrollment in the study if both clinical signs and laboratory tests meet the diagnosis standards of American Diabetes Association 2010. Other key inclusion criteria were presence of at least one autoantibody to the pancreatic islet β cells for the autoimmune-related type 2 diabetes.

Exclusion Criteria:

* Exclusion criteria were any clinically significant diseases in liver, kidney, and heart. Additional exclusion criteria were no pregnancy, no immunosuppressive medication, no viral diseases or diseases associated with immunodeficiency.
A Trial to Evaluate the Combination Efficacy of Artificial Dermis and Growth Factor in Chronic Wounds Ulcer

Double layer artificial dermis repair material has been widely used in scar plastic, burn, trauma, chronic wounds and other aspects of wound repair and reconstruction. In the course of clinical application, we found that for chronic wounds, the combination of artificial dermis and growth factor can shorten the wound healing cycle, and have a positive impact on the economy and psychology of patients. In order to verify this effect, we plan to carry out this study to evaluate whether double-layer artificial dermis repair material combined with growth factor treatment can improve wound closure rate and shorten closure cycle compared with single artificial dermis for chronic wound.


Eligibility Criteria:
Inclusion Criteria:

1. Patients diagnosed as chronic wounds ulcer;
2. The affected limb has sufficient blood perfusion. The ankle brachial index was 0.65-1.3, or the partial pressure of oxygen was more than 40 mmHg, or Doppler ultrasound showed enough blood flow.
3. After debridement, the distance between the wound and the edge of other ulcers was \>2cm.
4. After debridement, the area of exposed bone or tendon was \>4cm2.
5. The wound was completely debridement without obvious necrosis, infection control or osteomyelitis control.
6. The duration of ulcer wound was at least 30 days.
7. Sign the informed consent voluntarily.

Exclusion Criteria:

1. Poor control of diabetes (fasting blood glucose ≥ 8.0mmol/l, HbA1c ≥ 12%);
2. The researchers think that there are factors affecting wound healing, such as the use of corticosteroids, immunosuppressants and other drugs, chemotherapy or radiotherapy within one year.
3. To receive or plan to receive drugs or treatment, the researchers believe that these drugs or treatment will interfere with or affect the speed and quality of wound healing;
4. Unstable Charcot's foot or Charcot's joint disease with bone protrusion;
5. Patients with severe lymphedema, coagulation disorders, autoimmune diseases, cardiovascular and cerebrovascular diseases, and severe hepatopulmonary and renal diseases;
6. Those who have received hyperbaric oxygen treatment within 5 days before enrollment, or who have received or plan to receive growth factor, tissue-engineered skin or other skin substitutes treatment within 30 days;
7. Those who have participated in or are participating in other clinical studies within 30 days before screening;
8. Pregnant, or lactating women;
9. Poor general condition or other conditions not suitable for the use of double-layer artificial leather repair materials;
10. Be allergic to collagen or chondroitin sulfate;
11. Other cases that researchers think are not suitable for the participation.
Chlorthalidone and HCTZ Impacts on Platelet Activation

This will be a randomized, double-blinded, three-period crossover study of platelet activation and aggregation in 30 non-smoking healthy volunteers comparing chlorthalidone (CTD), hydrochlorothiazide (HCTZ), and aspirin (ASA; active control). The study hypothesis is that CTD has different effects on platelet activation and aggregation than HCTZ.


Eligibility Criteria:
Inclusion Criteria:

* Men or women age 19 or older
* Not currently taking any routinely scheduled prescription or over the counter medications or herbal supplements
* No use of aspirin, clopidogrel, prasugrel, ticagrelor, cilostazol, dipyridamole, NSAID medications, or herbal supplements within the previous 7 days and able to refrain from use during the study period
* Systolic blood pressure \> 110 mmHg and diastolic blood pressure \> 60 mmHg
* Non-smoker

Exclusion Criteria:

* Previous adverse reaction or allergy to HCTZ, CTD, or ASA
* Severe sulfonamide hypersensitivity (anaphylaxis or Stevens-Johnson syndrome)
* Diagnosis of any chronic disease or condition
* History of gout or hyperuricemia
* History of pancreatitis
* History of systemic lupus erythematosus (SLE)
* History of hypokalemia requiring treatment
* Pregnant or planning to become pregnant during the study period
* Breastfeeding
* History of hypotension
* History of gastrointestinal bleeding
A Clinical Study to Evaluate the Efficacy and Satisfaction of the Skinceuticals Skin Care Product (CE) for Skin Repair Post Fraxel Laser Treatment

A Prospective, Single-center, Single-blind, Randomized split-face, controlled trial will be conducted. The goal of this clinical trial is to evaluate the efficacy and satisfaction of the Skinceuticals skin care product (CE) for skin repair following fraxel laser treatment and explore the medical value of fraxel laser therapy combined with Skinceuticals skin care product


Eligibility Criteria:
Inclusion Criteria:

1. Chinese subjects aged 18-65 years (inclusive);
2. Subjects with Fitzpatrick skin type II-IV;
3. Subjects with consistent facial skin status on both sides and planned to receive fraxel laser treatment;
4. Subjects are willing to follow the requirements of the study protocol and complete the corresponding procedures;
5. Subjects understand the nature of the study and sign the informed consent form (ICF).

Exclusion Criteria:

1. Subjects with photosensitive skin or photosensitization-related diseases;
2. Subjects with a history of skin pigmentation, such as pigmentation caused by sex hormone factors (pregnancy, oral contraceptives);
3. Subjects with hypertrophic scar or scar constitution;
4. Subjects with autoimmune diseases, endocrine diseases or liver diseases that may lead to skin color changes;
5. Subjects who have received steroid/phototoxic drugs or laser treatment on the face within 3 months before enrollment;
6. Subjects with a history of sun exposure within 2 weeks prior to enrollment;
7. Subjects who are known to be contraindicated to fraxel laser therapy or CE (or allergic to other skin care components);
8. Subjects with known infection and inflammation in the intended treatment site;
9. Female subjects who are pregnant, lactating or plan to become pregnant;
10. Subjects who plan to use other drugs affecting skin color or intend to undergo other laser therapy and sunbathing during the treatment;
11. Subjects who are participating in other drug or medical device clinical trials;
12. Other subjects who are not suitable for this study as assessed by the investigator
Assessment of Treatment Safety and Quality of Life in Patients Receiving Etanercept Biosimilar for Autoimmune Arthritis

In this open-label, multi-center, observational, post-marketing surveillance study, patients with ankylosing spondylitis, psoriatic arthritis, or rheumatoid arthritis received biosimilar etanercept 25 mg twice weekly or 50 mg once weekly in real-world settings. Safety and effectiveness of biosimilar etanercept were evaluated in study participants for a duration of up to 12 months.

In this open-label, multi-center, observational, post-marketing surveillance study, patients with ankylosing spondylitis, psoriatic arthritis, or rheumatoid arthritis received biosimilar etanercept 25 mg twice weekly or 50 mg once weekly in real-world settings. Safety and effectiveness of biosimilar etanercept were evaluated in study participants for a duration of up to 12 months. Patient information was recorded in four notebooks, and each notebook had three sections, one section for each month. The first section of notebook I contained demographic information, pregnancy and lactation status in female patients, cigarette smoking and alcohol consumption, and past medical history. All safety and effectiveness outcomes were recorded at the appropriate sections of the notebooks.

Eligibility Criteria:
Inclusion Criteria:

* Adults with the diagnosis of rheumatoid arthritis, ankylosing spondylitis, or psoriatic arthritis receiving biosimilar etanercept (either 25 mg or 50 mg) for their medical condition.

Exclusion Criteria:

* No strict exclusion criteria were applied.
Immunoadsorption in Patients With Severe Systemic Sclerosis

The purpose of this study is to evaluate source data for the survival and the investigation of the preliminary efficacy of immunoadsorption in patients with severe systemic sclerosis.


Eligibility Criteria:
Inclusion Criteria:

* systemic sclerosis according to the ACE-criteria
* severe pulmonary manifestation with reduced DLCO
* signed informed consent

Exclusion Criteria:

* inadequate peripheral venous access
* participation in another clinical trial
* heart failure
* pronounced allergic diathesis, particularly in case of known hypersensitivity to drugs and/or materials used in the extracorporeal circuit
The Effect of Electronic Cigarette Liquid Characteristics in Smokers.

The purpose of this study is to determine differences in nicotine delivery, user behaviors, subjective effects, and physiological effects, when cigarette smokers use an electronic cigarette with different nicotine (and sweetener) concentrations relative to using their own brand of cigarettes.


Eligibility Criteria:
Inclusion Criteria-- Participants must be:

* Healthy (determined by self-report)
* Between the ages of 21-55 years old
* Current cigarette smokers
* Wiling to provide informed consent
* Able to attend the lab session and abstain from tobacco/nicotine products as required
* Agree to use designated products according to the study protocol

Exclusion Criteria:

* Women if they are breast-feeding or test positive for pregnancy (by urinalysis) at screening.
* Individuals who weigh less than 110 pounds.

Some study details about the eligibility criteria are purposely omitted at this time to preserve scientific integrity. Full details will be posted at the conclusion of the study.
Age-related Variability of the Efficacy and Tolerability of Alternative Pituitary Suppression Regimens in ART

Age-related variability of the efficacy and tolerability of alternative pituitary suppression regimens in follicular stimulation for assisted reproduction purposes. A randomised, prospective, multi-centre clinical trial

Pituitary suppression is strongly advised to be included within the follicular stimulation protocols to avoid the occurrence of a premature LH surge, which leads to cycle cancellation.

However, whatever the drug and the schedule selected to achieve it, it is clear that pituitary suppression constitute a major perturbation of the endocrine milieu and that it has an impact on the outcome of the stimulation.

Indeed, the data in the literature support the idea that pituitary down-regulation by GnRH agonists according to the so-called long protocol, resulting in a deeper suppression, result in better clinical outcomes as compared to the short protocol, at least in women of younger reproductive age. Conversely, it has been proposed that a less profound suppression (e.g. short protocol), that allows better background regulation from the pituitary, should be preferred in women of advanced reproductive age.

However, the majority of the data currently supporting the decision makers in selecting their pituitary suppression strategies is based on studies focussed on standard, good prognosis patients whereas just a few studies have specifically addressed the special issue of the advanced reproductive age. Inasmuch, very few data are available in pure (non resistant) advanced age patients and, however, no studies have compared in the same setting younger vs aged subjects with an adequate sample size.

Another intriguing aspect of the question is that the chronological age does not necessarily overlap with the reproductive age which, besides complicating the decisional process in the clinical practise, may also play as a confounding factor in the evaluation of the results from clinical trials. Several studies have validated the role of the so-called follicle antral count (AFC) and the anti-Mullerian hormone (AMH) circulating levels as having a predictive role in the evaluation of the actual reproductive age. In particular the latter, the AMH, appears to be easier to standardise and to be used as the best reference in multicentre clinical studies focussed on the reproductive age.

In summary, there is a clear lack of information on the performance of the different GnRH-agonist schedules in alternative chronological and reproductive age groups and the data from a large size prospective trial may generate valuable indications for the daily clinical practise.

Eligibility Criteria:
Inclusion Criteria:

* Age 18 to 42
* First IVF attempt
* BMI 18 to 25
* Basal FSH less than 12 for subjects below the age of 35 or less than 15 for subjects aged more than 35
* Informed consent

Exclusion Criteria:

* Genital malformation
* Hypersensitivity to study drugs
* Major illnesses (to be specified)
* PCOS
Hearing Aid Quality and Reliability Study

Quality and reliability study of hearing aid. Adults with mild to severe hearing loss will wear hearing aids daily for approximately 3 months.


Eligibility Criteria:
Inclusion Criteria:

* Adults with mild to moderate severe sensorineural hearing loss
* Adults who were able to incorporate some type of physical activity into their day (i.e walking, excercise, gardening, etc.)

Exclusion Criteria:

* Unable or unwilling to wear study devices during a home trial
* Unable or unwilling to come to lab for study visits
Antler Plate on Preventing Mammary High-risk Lesions From Malignant Development

This study aims to prove whether antler disk extract can be put into clinical practice to prevent breast precancerous lesions from developing into cancer.

Through estrogen receptor antagonists, tamoxifen can reduce the risk of breast high-risk disease progression to cancer, but only reduce the probability of some ER and PR positive tumors, which has no preventive effect on triple negative breast cancer and HER-2 positive breast cancer. In the first hospital of Jilin University, the preparations containing antler ingredients have been clinically proven to be able to treat breast hyperplasia, which has been proved to be able to prevent breast cancer in basic research, and antler ingredients have been proved to be non-toxic and side effects in the treatment dose. This study aims to prove whether antler disk extract can be put into clinical practice to prevent breast precancerous lesions from developing into cancer.

Eligibility Criteria:
Inclusion Criteria:

* Women between the ages of 18 and 80
* Atypical hyperplasia or / and lobular carcinoma in situ confirmed by breast histology
* Women with breast cancer in first degree relatives
* Patients have better compliance with a series of research-related behaviors such as the upcoming comprehensive treatment and follow-up, and can understand and accept the research process of this study, and sign a written informed consent

Exclusion Criteria:

* Hepatorenal dysfunction, cardiovascular and cerebrovascular diseases
* Patients not suitable for this study judged by researchers
Uterine and Endometrial Volume in PCOS and HPOD

Group II causes of anovulation according to the World Health Organization include polycystic ovary syndrome (PCOS) and the less common dysfunction of the hypothalamic-pituitary-ovarian axis (HPOD). Assessment of ovarian volume, number and morphology of ovarian follicles is essential in the diagnosis of menstrual disorders, including PCOS and HPOD. However, the uterus is a target organ for steroid hormones, and the assessment of uterine size and endometrial morphology may also be of clinical importance. While ultrasonographic features of the ovaries in PCOS have been described and constitute one of the diagnostic criteria for the syndrome (Rotterdam criteria), there is little data on uterine volume in women with PCOS and HPOD. The aim is to compare ultrasound i) uterine volume and ii) endometrial volume among women with PCOS and women with HPOD.

Group II causes of anovulation according to the World Health Organization include polycystic ovary syndrome (PCOS) and the less common dysfunction of the hypothalamic-pituitary-ovarian axis (HPOD). The exact etiology of both entities is unknown. The diagnosis of PCOS requires meeting the Rotterdam criteria. HPOD, in turn, is considered a functional disorder of the axis, related to lifestyle factors, and the diagnosis is made after excluding identifiable causes of ovulation disorders. Assessment of ovarian volume, number and morphology of ovarian follicles is essential in the diagnosis of menstrual disorders, including PCOS and HPOD. However, the uterus is a target organ for steroid hormones, and the assessment of uterine size and endometrial morphology may also be of clinical importance. The dimensions and volume of the uterus and endometrium may influence the clinical pregnancy rate in women undergoing assisted reproductive technologies. Both too small and too large sizes and volumes of the uterus may reduce the rate of clinical pregnancies. Too small dimensions may result from hypoestrogenism, while excessive size may be the result of estrogen-progesterone imbalance accompanying PCOS, increased uterine vascularity, as well as estrogen-dependent changes in the uterine myometrium, such as adenomyosis. Similarly, too "thin" endometrium and too thick (cystic) endometrium may reduce the receptivity of the endometrium. While ultrasonographic features of the ovaries in PCOS have been described and constitute one of the diagnostic criteria for the syndrome (Rotterdam criteria), there is little data on uterine volume in women with PCOS and HPOD. The aim is to compare ultrasound uterine volume and endometrial volume among women with PCOS and women with HPOD. The volume of the uterus will be determined according to the formula: V = (π/6) × length × width × height (in cm and given in ml). The volume of the endometrium will also be measured according to a similar formula.

Eligibility Criteria:
Inclusion Criteria:

* age 18-45 years
* no previous diagnosis and treatment due to menstrual disorders or infertility

Exclusion Criteria:

* previous ovarian surgery
* use of drugs that disturb the functions of the hypothalamic-pituitary-ovarian axis
* uterine tumors
Safety and Efficacy Study of Interferon Gamma-1b in Hepatitis C Patients With Liver Fibrosis or Cirrhosis

The purpose of this research study is to test the safety and effectiveness of Interferon gamma-1b (IFN-g 1b) injected subcutaneously (under the skin) for the treatment of advanced liver fibrosis and cirrhosis in patients with chronic hepatitis C infections.

IFN-g 1b is not currently approved for the treatment of liver fibrosis.

This study will evaluate the safety and tolerability of IFN-g 1b in patients with advanced liver fibrosis and cirrhosis due to hepatitis C. This study will also evaluate whether IFN-g 1b is effective in reducing the amount of fibrosis in the liver.

Eligibility Criteria:
* Men or women 18 to 75 years
* Chronic hepatitis C infection based on a history of positive anti-HCV antibody and/or HCV RNA
* History of prior treatment with interferon-a-based therapies or an assessment by the investigator that the patient would not benefit from interferon-a-based therapy or that treatment with interferon-a is contraindicated
* Stage 4, 5 or 6 liver fibrosis according to the Ishak scoring system.
* Cannot have presence of clinically evident ascites requiring active diuretic therapy, history of or therapy for hepatic encephalopathy, or history of GI variceal bleeding within the last 2 years (diuretic therapy of stable mild-to-moderate peripheral edema is permitted)
* Must meet minimum blood chemistry requirements
* Cannot have unstable or uncontrolled thyroid disease
* Cannot have a variety of other diseases (listed in protocol
* Other conditions for enrollment exist which would be discussed with a Clinician upon screening for the study.